AI Article Synopsis
- The study aimed to explore gender differences in the response to the SSRI citalopram for treating depression, analyzing data from a large sample of 2,876 patients.
- The findings revealed that women, despite presenting with more severe depressive symptoms and various comorbid conditions at the start, were more likely than men to achieve remission and respond positively to the treatment.
- The research suggests that these differences in response may be linked to biological factors related to serotonin systems in men and women.
Article Abstract
Objective: Controversy exists as to whether women with depression respond better to selective serotonin reuptake inhibitors (SSRIs) than men. The purpose of this report was to determine whether men and women differ in their responses to treatment with the SSRI citalopram using a large sample of real world patients from primary and psychiatric specialty care settings.
Method: As part of the sequenced treatment alternatives to relieve depression (STAR *D) study, 2876 participants were treated with citalopram for up to 12-14 weeks. Baseline demographic and clinical characteristics and outcomes were gathered and compared between men and women.
Results: At baseline, women were younger, had more severe depressive symptoms and were more likely to have: early onset; previous suicide attempt(s); a family history of depression, alcohol abuse or drug abuse; atypical symptom features; and one or more of several concurrent psychiatric disorders. Despite greater baseline severity and more Axis I comorbidities, women were more likely to reach remission and response with citalopram than men.
Conclusions: Women have a better response to the SSRI citalopram than men, which may be due to sex-specific biological differences particularly in serotonergic systems.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681489 | PMC |
| http://dx.doi.org/10.1016/j.jpsychires.2008.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation.
Clin Pharmacol Ther
December 2024
College of Pharmacy, CHA University, Seongnam-si, Gyeonggi-do, South Korea.
Escitalopram is commonly prescribed for depressive and anxiety disorders in elderly patients, who often show variable drug responses and face higher risks of side effects due to age-related changes in organ function. The CYP2C19 polymorphism may further affect escitalopram pharmacokinetics in elderly patients, complicating dose optimization for this group. Previous pharmacogenetic studies examining the impact of CYP2C19 phenotype on escitalopram treatment outcomes have primarily focused on younger adults, leaving a gap in understanding its effects on the elderly.
View Article and Find Full Text PDFDepression is Associated with Treatment Response Trajectories in Adults with Prolonged Grief Disorder: A Machine Learning Analysis.
medRxiv
December 2024
Department of Psychiatry, New York University Grossman School of Medicine, New York, New York.
Unlabelled: Although evidence-based treatments for Prolonged Grief Disorder (PGD) exist, pretreatment characteristics associated with differential improvement trajectories have not been identified. To identify clinical factors relevant to optimizing PGD treatment outcomes, we used unsupervised and supervised machine learning to study treatment effects from a double-blinded, placebo-controlled, randomized clinical trial. Participants were randomized into four treatment groups for 20 weeks: citalopram with grief-informed clinical management, citalopram with prolonged grief disorder therapy (PGDT), pill placebo with PGDT, or pill placebo with clinical management.
View Article and Find Full Text PDFDifferential effects of pharmaceuticals and insecticides on swimming behaviour and survival in Gammarus pulex.
Sci Total Environ
December 2024
Aquatic Ecology and Water Quality Management Group, Wageningen University and Research, 6700AA Wageningen, the Netherlands. Electronic address:
Many freshwater systems are continuously exposed to waste streams like municipal wastewater and agricultural runoff, leading to exposure to chemicals that can cause mortality and behavioural changes in aquatic organisms. While research has advanced our understanding of pesticide effects on behaviour of aquatic organisms, the impacts of pharmaceuticals are less understood. Psychopharmaceuticals are particularly interesting because they can act on nervous systems, potentially affecting the behaviour of aquatic organisms.
View Article and Find Full Text PDFInvestigation of Pharmacokinetic and Pharmacodynamic Interactions between Citalopram and Duloxetine: An Integrated Analytical, Computational, Behavioral, and Biochemical Approach.
ACS Pharmacol Transl Sci
December 2024
School of Biotechnology, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt.
Despite the prevalent utilization of antidepressant combinations in clinical settings, concerns persist regarding heightened side effects and potential drug-drug interactions (DDI). In response, this study investigates the interaction between citalopram (CIT) and duloxetine (DUL) using a multifaceted approach encompassing analytical, computational, behavioral, and biochemical techniques. Notably, the absence of published analytical methods tailored for studying antidepressant interactions underscores the novelty of our endeavor.
View Article and Find Full Text PDFPharmacotherapeutic actions related to drug interaction alerts - a questionnaire study among Swedish hospital interns and residents in family medicine.
Eur J Clin Pharmacol
February 2025
Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Purpose: To explore how hospital interns and residents specialising in family medicine act on drug interaction alerts in a specific patient case, and on interaction alerts in general.
Methods: A 4-page questionnaire, including a fictional patient case (73-year-old woman; 10 drugs in the medication list triggering 11 drug interaction alerts) and questions regarding the use of interaction alerts in general, was distributed to interns and residents during educational sessions (November‒December 2023). The respondents were instructed to consider what actions they would take "a normal day at work" due to the risk of interactions between the patients' drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!